Meta-analysis of repaglinide versus mitiglinide in treatment of type 2 diabetes

WEI Jin-fei; ZHOU Liang; WANG Xiao-qing; ZHANG Xin; WANG Xin-hui; WANG Ming-mei

Abstract：[AbstrAct]Objective:To evaluate the efifcacy and safety of repaglinide versus mitiglinide in type 2 diabetes (T2DM). Methods: PubMed, Medline, EMbase, Cochrane Library, Wanfang, VIP, CNKI and CHKD databases were retrieved. The data about randomized controlled trials (RCTs) of repaglinide and mitiglinide in type 2 diabetes treatment was collected and assessed by Cochrane Handbook 5.1.0 collaboration system, and then meta-analysis was performed using RevMan 5.2 software.results: A total of 5 RCTs including 390 patients met the inclusion criteria. The results of meta-analysis showed that the effects of repaglinide in lowering HbAlc [MD = 0.02, 95%CI(–0.43, 0.48),P = 0.92] and FPG [MD = 0.33, 95%CI (0.00, 0.66),P = 0.05] were similar to those of mitiglinide. Mitiglinide significantly reduced 2 hPG [MD = 0.91, 95%CI(0.42, 1.39),P = 0.000 3] comparing with repaglinide. No signiifcant difference was observed in gastrointestinal discomfort [OR = 0.61, 95%CI(0.15, 2.48),P = 0.49] between the two groups, but the risk of hypoglycemia [OR = 5.71, 95%CI(2.16, 15.10),P = 0.000 4] in repaglinide group was higher than that of mitiglinide group.conclusion:In the treatment of T2DM, mitiglinide showed more effective in 2 hPG and lower risk of hypoglycemia than repaglinide. Limited by the methodological quality and sample amount of included studies, this conclusion needs to be veriifed by large sample, strict design and long-term follow-up RCTs.